Can-Fite BioPharma
  • ABOUT
    • Overview
    • Management
    • Drug Development Team
    • Board of Directors
    • Corporate Partnerships
  • SCIENCE
    • Technology Platform
    • Scientific Publications
  • PIPELINE
    • Overview
    • Piclidenoson (CF101)
    • Namodenoson (CF102)
    • CF602
    • Cannabinoids
  • INVESTORS
    • Overview
    • News & Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Fillings
    • Corporate Governance
    • Shareholders Meetings
  • CONTACT

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In The News
    • Research
    • Events Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Video
    • Management
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Governance Documents
  • Shareholders Meetings
  • News & Events

  • Overview
  • Press Releases
  • In The News
  • Research
  • Events Calendar
  • Presentations
  • Email Alerts
Dec 29, 2021 7:00am EST

Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors

Dec 20, 2021 4:05pm EST

Can-Fite Announces Exercise of Warrants for Cash Proceeds of $10 Million

Dec 20, 2021 7:00am EST

Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

Dec 07, 2021 7:00am EST

Can-Fite’s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022

Nov 26, 2021 7:00am EST

Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update

Nov 24, 2021 7:00am EST

Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021

Nov 23, 2021 7:00am EST

Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis

Nov 12, 2021 7:00am EST

Can-Fite to Present at H.C. Wainwright 7th Annual Israel Conference

Nov 01, 2021 7:00am EDT

Can-Fite’s Findings on Cannabis Compound’s Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD’s The Liver Meeting® 2021 Conference

Oct 28, 2021 7:00am EDT

Can-Fite’s NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico

  • arrow_back
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 45
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • HOME
  • CONTACT

© 2025 Can-Fite All Rights Reserved

BrandWiz - Branding